two
highli
pathogen
human
coronavirus
associ
sever
respiratori
syndrom
emerg
sinc
begin
centuri
sever
acut
respiratori
syndrom
sarscoronaviru
cov
spread
first
southern
china
infect
case
month
middl
east
respiratori
syndrom
merscov
emerg
arabian
peninsula
give
still
ongo
epidem
associ
high
fatal
rate
cov
thu
consid
major
health
threat
especi
true
vaccin
specif
therapeut
avail
either
sarsor
merscov
therefor
new
drug
need
identifi
order
develop
antivir
treatment
limit
cov
replic
studi
focu
protein
play
key
role
viru
replic
methyl
rna
cap
structur
posit
guanin
develop
highthroughput
assay
base
homogen
time
resolv
fluoresc
htrf
screen
chemic
librari
compound
sarscov
compound
inhibit
sarscov
evalu
ic
determin
specif
assess
toward
flavivirusand
human
cap
result
reveal
three
class
compound
molecul
inhibit
sever
mtase
well
dengu
viru
polymeras
activ
unspecif
pan
mtase
inhibitor
target
viral
cellular
mtase
inhibitor
target
one
viral
mtase
specif
show
howev
activ
human
cap
compound
provid
first
basi
toward
develop
specif
inhibitor
viral
methyltransferas
sever
acut
respiratori
syndrom
coronaviru
sarscov
spread
china
respons
worldwid
outbreak
caus
infect
peopl
fatal
rate
around
de
wit
et
al
novel
human
coronaviru
name
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
arabian
peninsula
secondari
infect
case
report
europ
america
asia
africa
merscov
infect
result
confirm
infect
patient
till
april
fatal
rate
de
wit
et
al
cov
envelop
virus
possess
singl
strand
posit
sens
rna
genom
approxim
kb
length
pan
et
al
van
boheemen
et
al
sarscov
initi
replic
cycl
bind
angiotensinconvert
enzym
kuhn
et
al
endocytosi
viral
rna
genom
releas
cellular
host
cytoplasm
translat
two
larg
polyprotein
de
wit
et
al
snijder
et
al
polyprotein
next
cleav
viral
proteas
nonstructur
protein
respect
protein
form
larg
replic
transcript
complex
rtc
associ
host
cellular
protein
van
hemert
et
al
cov
rtc
ensur
replic
viral
genom
transcript
genom
subgenom
mrna
viral
rna
polyadenyl
end
protect
cap
structur
synthet
viral
enzym
cov
cap
pathway
thought
follow
four
sequenti
step
implic
sever
nsp
helicas
ntpase
hydrolys
first
phosphat
g
nascent
rna
ivanov
ziebuhr
ii
gmp
molecul
supposedli
transfer
diphosphoryl
rna
still
unknown
guanylyltransferas
form
cap
gpppn
structur
iii
cap
methyl
posit
guanosin
presenc
methyl
donor
sadenosyllmethionin
sam
yield
gpppn
sadenosyllhomocystein
sah
byproduct
chen
et
al
iv
complex
methyl
ribos
oh
group
first
transcrib
rna
lead
convers
gpppn
gpppn
bouvet
et
al
chen
et
al
vitro
assay
deciph
mechan
drive
rna
cap
methyl
sarsand
merscov
follow
obligatori
order
prerequisit
omethyl
complex
aouadi
et
al
bouvet
et
al
bouvet
et
al
guanin
activ
embed
ctermin
domain
discov
yeast
transcomplement
assay
chen
et
al
addit
nterminu
moieti
contain
deddh
exonucleas
exon
domain
minskaia
et
al
two
domain
commun
function
truncat
experi
show
ntermin
region
requir
activ
chen
et
al
exon
activ
confirm
vitro
assay
show
associ
stimul
fold
exon
activ
activ
depend
interact
bouvet
et
al
bouvet
et
al
decroli
et
al
omethyl
viral
mrna
cap
key
event
viral
infect
inde
revers
genet
experi
reveal
first
cap
structur
essenti
synthesi
viral
protein
case
et
al
observ
corrobor
former
biochem
data
show
guanosin
cap
structur
recogn
eukaryot
translat
initi
factor
particip
initi
viral
mrna
translat
protein
case
et
al
cougot
et
al
accordingli
inhibitor
block
activ
identifi
yeast
base
screen
assay
sarscov
induc
potent
antivir
effect
demonstr
mtase
activ
attract
antivir
target
sun
et
al
wherea
mutant
replic
defect
omtas
mutant
show
limit
effect
viru
replic
cell
cultur
attenu
phenotyp
anim
model
menacheri
et
al
zhang
et
al
et
al
molecular
basi
attenu
phenotyp
recent
elucid
incompletelycap
rna
shown
recogn
immun
sensor
rigi
trigger
innat
immun
pathway
schuberthwagn
et
al
wu
et
al
turn
rigi
induc
signal
cascad
yield
express
cytokin
type
interferon
induc
antivir
state
neighbor
cell
among
interferonstimul
gen
isg
also
particip
restrict
viral
replic
sequestr
miscap
viral
rna
pichlmair
et
al
thu
cap
structur
consid
kind
marker
self
current
admit
omtas
inhibitor
might
help
viru
clearanc
stimul
immun
respons
ferron
et
al
et
al
work
first
develop
htrf
mtase
assay
order
identifi
compound
inhibit
activ
sarscov
use
system
screen
librari
compos
compound
contain
fda
approv
molecul
prestwick
chemic
librari
natur
product
pyridazinederiv
compound
inhibitori
effect
best
compound
confirm
radioact
filterbind
assay
refin
ic
valu
determin
sar
human
rna
hrnmt
addit
specif
compound
evalu
use
cov
omtas
mtase
dengu
westnil
flavivirus
well
hrnmt
involv
cap
cellular
rna
prestwick
chemic
librari
uniqu
collect
small
molecul
mostli
approv
drug
fda
ema
agenc
select
high
chemic
pharmacolog
divers
well
known
bioavail
safeti
human
prestwick
phytochem
librari
collect
natur
product
mostli
deriv
plant
assembl
medicin
chemist
rich
divers
chemotyp
thu
realist
followup
chemistri
prestwick
pyridazin
librari
collect
innov
pyridazin
pyridazon
deriv
base
seri
care
select
new
origin
scaffold
molecul
design
ensur
optim
divers
suitabl
divers
chemic
modif
viral
mtase
sarscov
merscov
west
nile
viru
human
rna
rnmt
code
sequenc
clone
fusion
nterminu
hexahistidin
tag
gateway
plasmid
life
technolog
protein
express
e
coli
cell
purifi
follow
previous
describ
protocol
aouadi
et
al
bouvet
et
al
et
al
milha
et
al
peyran
et
al
selisko
et
al
merscov
produc
purifi
follow
protein
express
arctic
express
e
coli
strain
agil
c
h
addit
mm
iptg
bacteria
pellet
g
c
min
lyse
sonic
appropri
buffer
mm
trishcl
ph
mm
nacl
glycerol
mm
imidazol
mm
bmercaptoethanol
mm
pmsf
mgml
dnasei
mgml
lysozym
clarif
g
min
c
recombin
protein
purifi
immobil
metal
affin
chromatographi
imac
ml
hispurtm
cobalt
resin
thermo
scientif
follow
size
exclus
chromatographi
superdex
ge
healthcar
equilibr
mm
hepe
ph
mm
nacl
glycerol
purifi
protein
analyz
sdspage
gel
coomassi
blue
stain
fig
fig
initi
screen
nl
compound
resuspend
dmso
mm
dispens
reaction
volum
final
dmso
mm
compound
use
mosquito
crystal
pipet
robot
platform
ttp
labtech
dmso
sinefungin
mm
sah
mm
use
control
enzymat
reaction
perform
ml
ml
mix
buffer
sar
nm
final
concentr
ad
assay
well
contain
previous
dispens
inhibitor
ml
use
biomek
nx
mc
pipet
robot
beckman
reaction
buffer
compos
trishcl
mm
ph
dtt
mm
final
concentr
reaction
start
ml
mix
contain
gpppa
neb
ref
sam
mm
mm
final
concentr
respect
incub
min
c
detect
releas
sah
methyltransferas
kit
purchas
cisbio
bioassay
reconstitut
accord
supplier
protocol
htrf
assay
perform
white
well
small
hibas
polystyren
micropl
greiner
final
volum
ml
ml
epigen
detect
buffer
one
ml
nacl
ad
order
stop
reaction
min
incub
room
temperatur
detect
reagent
ad
ml
dilut
sah
conjug
floresc
dye
first
place
ml
antisah
dilut
htrf
signal
measur
h
final
incub
room
temperatur
use
pherastarf
bmg
labtech
excit
filter
nm
fluoresc
wavelength
measur
nm
integr
delay
ms
integr
time
ms
result
analyz
twowavelength
signal
ratio
intens
nm
intens
nm
htrf
ratio
normal
htrf
ratio
calcul
follow
compound
signal
min
signal
max
signal
min
signal
max
signal
signal
ratio
without
protein
min
signal
signal
ratio
dmso
place
compound
z
factor
calcul
use
follow
equat
z
e
sd
max
sd
min
mean
max
signal
mean
min
signal
sd
standard
deviat
ic
measur
valu
normal
fit
prism
graphpad
softwar
use
follow
equat
hill
slope
initi
screen
assay
perform
hit
confirm
determin
ic
htrf
quadrupl
ic
htrf
defin
compound
concentr
sah
releas
decreas
inhibitor
specif
assay
carri
reaction
mixtur
mm
trishcl
ph
mm
dtt
mm
mgcl
mm
sam
mm
hsam
perkin
elmer
presenc
mm
gpppac
gpppac
synthet
rna
purifi
nm
nm
mm
nm
hrnmt
nm
denvmt
nm
wnv
nm
enzym
mix
first
mm
inhibitor
addit
rna
substrat
sam
incub
c
final
concentr
dmso
control
reaction
perform
presenc
dmso
reaction
mixtur
stop
min
dilut
icecold
mm
sah
sampl
transfer
sarscov
encod
bifunct
enzym
contain
ntermin
exon
domain
follow
domain
involv
rna
cap
recombin
protein
purifi
immobil
metal
affin
chromatographi
imac
follow
size
exclus
chromatographi
purifi
detect
singl
band
migrat
expect
molecular
mass
fig
kda
coomassi
blue
stain
sdspage
gel
purifi
transfer
h
methyl
onto
gpppa
cap
analogu
wherea
mtase
activ
detect
onto
gpppa
fig
indic
harbor
activ
detect
use
cost
effect
commerci
cap
analogu
miniatur
epigen
mtase
assay
base
homogen
time
resolv
fluoresc
htrf
degorc
et
al
screen
librari
compound
principl
htrf
assay
shown
fig
follow
mtase
activ
indirectli
detect
sah
byproduct
methyl
transfer
reaction
inde
detect
system
releas
sah
compet
fluoresc
bind
antisah
antibodi
coupl
cryptat
fluorophor
see
materi
method
thu
increas
sah
lead
decreas
htrf
signal
fig
experiment
condit
enzymat
assay
optim
adapt
autom
screen
assay
briefli
enzym
concentr
set
nm
titrat
curv
indic
maxim
activ
min
incub
period
obtain
enzym
concentr
fig
ii
gpppa
substrat
concentr
adjust
mm
robustli
reproduc
detect
activ
fig
iii
sam
concentr
adjust
mm
order
ensur
optim
convers
rate
sam
sah
accord
manufactur
recommend
fig
sah
detect
condit
optim
antisah
antibodi
dilut
respect
fig
show
time
cours
experi
mtase
activ
indic
use
experiment
optim
condit
reaction
reach
satur
phase
min
incub
period
enzymat
reaction
thu
incub
min
screen
sinefungin
alreadi
report
inhibit
sarscov
ic
z
nm
bouvet
et
al
use
posit
control
mtase
inhibit
inhibit
curv
mtase
use
optim
htrf
assay
reveal
inhibit
similar
rang
ic
htrf
valu
nm
fig
also
assess
addit
dmso
impact
mtase
reaction
htrf
quantif
releas
sah
signal
variat
estim
averag
z
valu
chemic
librari
contain
fda
approv
molecul
natur
substrat
pyridazin
deriv
compound
use
initi
screen
mm
compound
inhibit
determin
use
htrf
assay
compound
show
inhibit
mtase
activ
higher
correspond
increas
htrf
signal
fig
first
select
compound
fig
compound
discard
due
signal
interfer
htrf
assay
visual
inspect
remain
compound
hit
rate
tabl
select
ic
htrf
determin
htrf
result
present
tabl
indic
ic
htrf
vari
mm
among
ic
htrf
higher
ic
htrf
determin
due
intrins
fluoresc
interfer
high
concentr
thu
compound
show
ic
htrf
rang
mm
order
valid
inhibit
observ
htrf
next
perform
radioact
mtase
assay
fba
use
freshli
solubil
compound
experi
mtase
activ
analyz
measur
h
radiolabel
methyl
transfer
onto
longer
synthet
rna
substrat
gpppac
cap
rna
previous
evidenc
better
substrat
cap
analogu
gpppa
bouvet
et
al
low
inhibit
compound
show
ic
htrf
mm
htrf
confirm
fba
assay
addit
fluoresc
compound
poorli
inhibit
mtase
activ
fba
assay
final
eleven
compound
display
potent
inhibit
mm
concentr
use
radioact
assay
tabl
wherea
observ
discrep
htrf
fba
assay
coupl
compound
could
explain
differ
rna
substrat
length
use
assay
observ
good
correl
assay
tabl
inhibit
specif
compound
mm
mtase
polymeras
activ
use
deaefilt
bind
assay
compound
cluster
frame
accord
inhibit
specif
wide
rang
specif
inhibitor
nd
determin
specif
compound
analyz
measur
inhibit
profil
viral
cellular
mtase
detail
see
workflow
fig
thu
produc
purifi
sarsand
merscov
complex
omtas
full
length
west
nile
wnv
domain
dengu
virus
human
rna
hrnmt
fig
order
compar
inhibit
profil
inhibit
compound
mm
determin
fba
mtase
activ
measur
addit
also
test
whether
activ
inhibit
order
address
compound
specif
result
summar
tabl
show
among
best
sarscov
inhibitor
confirm
fba
tabl
show
larg
spectrum
inhibit
inhibit
test
mtase
well
rdrp
tabl
also
reveal
sinefungin
use
posit
control
compound
exhibit
broad
spectrum
mtase
inhibit
profil
inhibit
detect
rdrp
activ
denv
broadspectrum
inhibit
observ
sinefungin
alreadi
report
relat
structur
homolog
samsah
dong
et
al
interestingli
compound
inhibit
mainli
cov
omtas
well
hrnmt
bare
interfer
wnv
mtase
activ
final
four
last
compound
show
specif
inhibit
profil
mersand
sarscov
although
inhibit
hrnmt
character
eleven
potent
inhibitor
dose
respons
curv
perform
compound
show
percentag
inhibit
higher
equal
sarscov
hrnmt
preincub
increas
concentr
inhibitor
mtase
activ
follow
fba
ic
compound
either
hrnmt
activ
rang
nm
mm
nm
mm
respect
confirm
observ
inhibit
potenc
molecul
tabl
addit
ic
valu
determin
assay
corrobor
perform
htrf
assay
tabl
broad
spectrum
mtase
inhibitor
show
ic
valu
mm
sar
human
hrnmt
respect
four
compound
target
specif
sar
mer
hrnmt
ic
valu
mm
ic
valu
observ
hrnmt
lower
case
altogeth
result
suggest
structur
homolog
viral
cellular
mtase
might
impair
discoveri
inhibitor
target
specif
cov
see
discuss
homolog
nevertheless
also
observ
less
activ
inhibitor
sarscov
bare
inhibit
human
hrnmt
suggest
possibl
identifi
specif
mtase
inhibitor
tabl
structur
activ
relationship
sar
studi
requir
order
gain
activ
specif
follow
confirm
compound
analog
tabl
comparison
ic
valu
activ
compound
human
rnmt
activ
use
gpppauau
gpppac
substrat
respect
search
test
librari
analog
select
test
inhibit
sar
hrnmt
mtase
activ
fba
tabl
analog
bear
benzhydrylpiperazin
group
characterist
chemic
seri
righthand
side
structur
four
compound
lack
aromat
moieti
left
part
molecul
show
inhibit
sarscov
mtase
contrast
analog
carri
aromat
termin
ring
lefthand
side
inhibit
sarscov
activ
ic
mm
substitut
two
phenyl
ring
benzhydrylpiperazin
moieti
fluorin
chlorin
group
impact
inhibit
profil
compound
initi
select
origin
screen
inhibit
close
select
cutoff
inhibit
mm
compound
inhibit
hrnmt
sarscov
similar
level
although
bring
addit
specif
compar
compound
might
worth
sampl
larger
chemic
space
within
famili
identif
molecul
inhibit
viral
enzym
essenti
viru
replic
key
point
combat
emerg
virus
methyl
viral
mrna
cap
structur
essenti
step
viru
lifecycl
case
et
al
cougot
et
al
prevent
identif
foreign
rna
marker
host
cell
diamond
li
et
al
et
al
thu
enzym
mtase
involv
viral
rna
cap
consid
promis
antivir
target
develop
highthroughput
mtase
screen
assay
base
htrf
technolog
possess
advantag
featur
htrf
assay
allow
minim
nonspecif
fluoresc
emiss
introduc
time
delay
ms
initi
light
excit
fluoresc
measur
degorc
et
al
time
delay
limit
interfer
fluoresc
compound
screen
assay
inde
compound
interf
detect
system
among
consid
fals
posit
addit
nonfluoresc
enzymat
assay
fba
use
confirm
hit
obtain
primari
screen
initi
screen
perform
use
commerci
cap
analogu
substrat
gpppa
avail
high
amount
cap
rna
substrat
limit
step
screen
allow
identif
compound
inhibit
least
activ
inhibitori
effect
mm
tabl
compound
confirm
use
radioact
filterbind
assay
perform
longer
synthet
rna
substrat
gpppac
contrast
compound
bare
inhibit
mtase
activ
measur
gpppac
substrat
thu
like
use
gpppa
substrat
may
favor
identif
inhibitor
would
less
effici
longer
rna
substrat
weaker
inhibit
effect
observ
use
longer
rna
substrat
might
suggest
compound
interfer
rna
bind
site
enzym
one
import
issu
drug
discoveri
process
identifi
compound
inhibit
specif
viral
enzym
bare
activ
cognat
cellular
enzym
order
limit
cytotox
offtarget
effect
determin
compound
specif
earli
stage
screen
process
compar
inhibit
activ
compound
viral
mtase
sarsand
merscov
mtase
denv
wnv
mtase
cellular
mtase
hrnmt
involv
methyl
cap
structur
addit
also
test
compound
dengu
viru
polymeras
order
control
inhibit
specif
rdrp
activ
elimin
molecul
show
unspecif
inhibit
frequent
hitter
strategi
reveal
best
hit
identifi
activityscreen
campaign
potent
inhibit
mtase
test
well
dengu
viru
polymeras
also
observ
inhibitor
identifi
compar
screen
potent
inhibit
human
rna
hrnmt
compound
result
might
relat
structur
function
homolog
cov
human
hrnmt
limit
possibl
identifi
inhibitor
target
specif
cov
howev
would
like
propos
inhibitor
identifi
might
well
substrat
mimick
bind
conserv
substrat
pocket
sinc
protein
fold
hrnmt
significantli
differ
latter
deviat
classic
rossmanfold
mtase
also
noteworthi
work
perform
highli
activ
truncat
construct
hrnmt
use
low
concentr
nm
ic
determin
addit
also
possibl
truncat
hrnmt
less
select
lack
hrnmt
activ
miniprotein
ram
bind
domain
ram
protein
inde
previous
demonstr
ram
stabil
structur
posit
hrnmt
lobe
increas
specif
recruit
sam
varshney
et
al
high
inhibit
hrnmt
mtase
activ
may
overcom
presenc
alloster
activ
ram
may
allow
stringent
specif
compound
compar
screen
use
variou
mtase
also
reveal
sever
compound
show
larg
spectrum
mtase
inhibit
without
signific
activ
detect
dengu
viru
polymeras
use
control
compound
posit
control
sinefungin
pleiotrop
inhibit
observ
mtase
activ
suggest
despit
weak
primari
sequenc
conserv
enzym
common
structur
organ
rosmann
fold
characterist
viral
cellular
mtase
share
similar
enzymat
properti
observ
consist
common
structur
organ
conserv
sam
rna
andor
cap
bind
site
share
mtase
identif
broadspectrum
viral
mtase
inhibitor
may
offer
start
point
develop
new
antivir
compound
consid
molecul
could
interest
expect
sar
process
give
opportun
increas
specif
inhibit
properti
accordingli
sar
studi
previous
perform
flaviviru
mtase
demonstr
chemic
analog
sah
show
improv
activ
select
denv
mtase
relat
human
enzym
lim
et
al
crystal
structur
reveal
activ
sah
deriv
harbor
substitut
accommod
specif
caviti
conserv
flavivir
mtase
would
thu
relev
initi
structur
analysi
viral
mtase
complex
best
compound
order
improv
select
viral
omtas
consid
promis
antivir
target
inhibit
suppos
impair
mrna
translat
viral
protein
induc
stimul
innat
immun
system
infect
host
thu
current
accept
mtase
inhibitor
might
help
viru
clearanc
stimul
immun
respons
ferron
et
al
et
al
work
identifi
molecul
inhibit
activ
sarscov
chemic
librari
compos
compound
use
htrf
base
inhibit
assay
eleven
compound
demonstr
potent
inhibit
mm
concentr
use
radioact
assay
specif
compound
evalu
use
radioact
assay
cov
omtas
mtase
dengu
westnil
virus
well
human
rna
hrnmt
involv
cap
cellular
rna
compar
analysi
reveal
select
compound
cluster
class
bare
specif
inhibitor
panmtas
inhibitor
inhibit
viral
cellular
mtase
inhibitor
target
specif
one
viral
mtase
also
activ
hrnmt
latter
seri
inhibitor
may
repres
good
start
point
develop
antivir
target
cov
mtase
